ClinicalTrials.gg
CompletedNCT01692262PYRUSUpdated Jun 19, 2014

Investigating Safety, Tolerability and Efficacy of AZD5363 in Prostate Cancer.

A Phase 1 interventional study of Intermittent dosing of AZD5363 and Intermittent dosing of AZD5363 in Metastatic Castrate-Resistant Prostate Cancer (mCRPC),, Efficacy, and Safety and Tolerability,, sponsored by AstraZeneca. Completed at 8 sites in 2 countries. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-06-19.

Sponsored by AstraZeneca · Phase 1, Interventional, and Screening

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
59
Allocation
Non-randomized
Ages
18 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Prostatic Neoplasms by AstraZeneca — 15 open to participants now, 29 under way, 8 of them phase 3. Prostatic Neoplasms · AstraZeneca.

Enrollment
39th of 60
59 · median 110
Started
2012
the only one that year
Phase 1
13 of 91
1 open now
Registered
40th of 91
by date

Among the 91 studies in Prostatic Neoplasms by AstraZeneca, this one is the 39th largest by enrollment of the 60 interventional ones that give a count, is the only one that started in 2012, is one of 13 in phase 1, and was the 40th registered.

Prostatic Neoplasms

7,051 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

15 of the 91 studies in Prostatic Neoplasms by AstraZeneca are open now, in 12 countries. Recruiting first, the newest first:

10 more — sign in →

By country, each count listing its studies:

All 15 open studies →

Who these studies take

Of the 1,230 Prostatic Neoplasms studies recruiting now, 929 (76%) set no upper age limit and 76 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Prostatic Neoplasms by AstraZeneca, or all of them as a file.
02

Study summary

To investigate the safety, tolerability and anti-tumour activity of AZD5363, as monotherapy, in patients with metastatic Castrate-Resistant Prostate Cancer. AZD5363 will be investigated in patients who have progressed after chemotherapy (Part A) and in patients who have progressed before receiving chemotherapy (Part B).

Recruitment into Part A, Group 1 has been suspended. A new design for this group is currently being evaluated. Part A, group 2 patients (progressed after 1 or more 2nd generational anti-hormonal therapies) will receive AZD5363 480mg bid intermittently (4 days on/3days off).

Part B will only start if there is evidence of anti-tumour activity along with AZD5363 having an acceptable safety profile in Part A. Part B will be conducted in pre-chemotherapy patients on a dose and schedule selected from Part A.

Read the detailed description

A Phase Ib Multicentre Study of AZD5363 Monotherapy to Assess Anti-Tumour Activity, Safety, Tolerability, and Pharmacokinetics in Patients With Metastatic Castrate-Resistant Prostate Cancer (mCRPC) (PYRUS)

03

Conditions studied

  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
  • Efficacy,
  • Safety and Tolerability,
  • Pharmacokinetics,
  • Pharmacodynamics,
  • Tumour Response.

Keywords

  • Metastatic Castrate-Resistant Prostate Cancer (mCRPC),
  • adenocarcinoma of the prostate,
  • prostate cancer,
  • progressive disease,
  • advanced disease.
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Provision of
  • Males aged 18 years and older
  • confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features for which no standard therapy is currently considered appropriate
  • Documented evidence of Castrate-Resistant Prostate Cancer (mCRPC)
  • Part A: Patients must have received prior docetaxel-based chemotherapy for mCRPC and have a Circulating Tumour Cell score of 5;
  • Part B: Patients must have progressed before receiving any chemotherapy for mCRPC;

Exclusion criteria

Exclusion Criteria:

  • Any prior exposure to agents which inhibit AKT as the primary pharmacological activity
  • Any evidence of severe or uncontrolled systemic diseases, including uncontrolled hypertension, active bleeding diatheses, or active infection including , , and
  • Spinal cord compression or unless asymptomatic, treated, and stable and not requiring
  • abnormalities of glucose metabolism
  • Major surgery within the previous 4 weeks
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 1
Primary purpose
Screening
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
59 participants (actual)

Study arms

  • Experimental
    Part A Group 1 Intermittent

    Recruitment suspended and will not be re-opened. See intervention description below.

    Drug: Intermittent dosing of AZD5363

  • Experimental
    Part A Group 2 Intermittent

    Recruitment complete. See intervention description below.

    Drug: Intermittent dosing of AZD5363

  • Experimental
    Part B

    This part of the study will not be conducted following a review of data from Part A. See intervention description below.

    Drug: Intermittent dosing of AZD5363

Interventions

  • DrugIntermittent dosing of AZD5363

    Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Recruitment suspended and will not be re-opened.

  • DrugIntermittent dosing of AZD5363

    Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue to study withdrawal. Recruitment complete.

  • DrugIntermittent dosing of AZD5363

    Intermittent dosing of AZD5363: oral solid formulation, twice daily (480 mg bid 4 days on and 3 days off). Treatment to begin on Day 1 and to continue until study drug withdrawal. This part of the study will not be conducted.

06

What researchers measure

Primary outcomes

  1. Parts A and B: Anti-tumour activity by measurement of changes in circulating prostate-specific antigen (PSA)

    Time frame: PSA measured from baseline for every 4 weeks. Primary assessment is at 12 weeks

  2. Parts A and B: Anti-tumour activity by measurement of changes in circulating tumour cells (CTC)

    Time frame: CTC measured from baseline for every 4 weeks to week 12 (primary assessment) then measured every 12 weeks

  3. Parts A and B: Anti-tumour activity by measurement of malignant soft tissue response rate

    Time frame: Tumour assessments by RECIST v1.1 every 12 weeks from baseline up to disease progression or withdrawal of consent

  4. Parts A and B: Anti-tumour activity by measurement of metastatic bone disease status

    Time frame: Bone lesion assessments by bone scan (PCWG2) criteria every 12 weeks from baseline up to disease progression or withdrawal of consent.

Secondary outcomes

  1. Parts A and B: Safety and tolerability of AZD5363 in terms of adverse events, serious adverse events (including death) and safety measures: ECG, ECHO/MUGA, physical examination, pulse, blood pressure, weight and laboratory variables

    Time frame: Routine safety assessments, throughout the period that patients receive AZD5363 up to 28 days following discontinuation of study treatment.

  2. Parts A and B: AZD5363 PK: time to maximum plasma concentration, terminal rate constant,terminal half life, area under plasma concentration time curve, plasma clearance & volume of distribution

    Time frame: Multiple AZD5363 PK blood sample assessments.AZD5363 plasma concentration blood samples will be taken on Day 1(pre-dose,2,4,8 hours post-dose);D2(pre-dose);D8(continous) or D11(intermittent) (pre-dose and at 2,4,and 8 hours post-dose);D15,Cyc

  3. Parts A and B: Plasma concentrations of pharmacodynamic (PD) biomarker

    Time frame: Multiple PD blood sample assessments.PD blood samples will be taken on the same schedule as PK sample and then Day 1 of every 12 weeks thereafter, and at the discontinuation visit

  4. Parts A and B: Progression-free survival (PFS)

    Time frame: Tumour assessments by RECIST v1.1 every 12 weeks from baseline up to disease progression or withdrawal of consent.

  5. Parts A and B: Quality of life (QoL)

    EORTC QLQ-C15-PAL, EORTC QLQ-PR25, and EORTC QLQ-BM22 Questionnaires

    Time frame: QOL will be documented from date of randomization and for 12 weeks.

07

Study locations

8 sites
  • Research Site
    Sarasota, Florida, United States
  • Research Site
    Boston, Massachusetts, United States
  • Research Site
    Ann Arbor, Michigan, United States
  • Research Site
    Hackensack, New Jersey, United States
  • Research Site
    Nashville, Tennessee, United States
  • Research Site
    Cardiff, Wales, United Kingdom
  • Research Site
    London, United Kingdom
  • Research Site
    Southampton, United Kingdom
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2012, a primary completion of Jun 2014 and a completion of Jun 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2012
First posted
Sep 25, 2012
Start
Nov 2012
Primary completionActual
Jun 2014
CompletionActual
Jun 2014
Last update
Jun 19, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 19, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01692262
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Sep 25, 2012
Start date
Nov 2012
Primary completion
Jun 2014
Completion
Jun 2014
Last update
Jun 19, 2014

Study contacts

Paul Stockman, MBCHB, PHD
study director · AstraZeneca
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion